Harnessing the immune system in glioblastoma

[1]  Michael A Vogelbaum,et al.  First-in-human evaluation of the Cleveland Multiport Catheter for convection-enhanced delivery of topotecan in recurrent high-grade glioma: results of pilot trial 1. , 2019, Journal of neurosurgery.

[2]  K. Ligon,et al.  Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143 , 2018, Neuro-oncology.

[3]  H. Wakimoto,et al.  Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models , 2018, Clinical Cancer Research.

[4]  Dai Fukumura,et al.  Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges , 2018, Nature Reviews Clinical Oncology.

[5]  Hakho Lee,et al.  Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles , 2018, Science Advances.

[6]  D. Pardoll,et al.  The intestinal microbiome influences checkpoint blockade , 2018, Nature Medicine.

[7]  Ken Garber,et al.  Driving T-cell immunotherapy to solid tumors , 2018, Nature Biotechnology.

[8]  R. Satija,et al.  Single-cell RNA sequencing to explore immune cell heterogeneity , 2017, Nature Reviews Immunology.

[9]  E. Jaffee,et al.  Tumor Mutational Burden and Response Rate to PD-1 Inhibition. , 2017, The New England journal of medicine.

[10]  F. Lieberman,et al.  Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial , 2017, JAMA.

[11]  Stephen J. Schuster,et al.  Chimeric Antigen Receptor T Cells in Refractory B‐Cell Lymphomas , 2017, The New England journal of medicine.

[12]  R. Levy,et al.  Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.

[13]  N. Lemoine,et al.  Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent , 2017, Nature Communications.

[14]  Act Investigators.  Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial , 2017 .

[15]  F. Macian,et al.  Glioblastoma progression is assisted by induction of immunosuppressive function of pericytes through interaction with tumor cells , 2017, Oncotarget.

[16]  R. Grossman,et al.  HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial , 2017, JAMA oncology.

[17]  K. Mansfield,et al.  A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma , 2017, Science Translational Medicine.

[18]  K. Kerr,et al.  Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  B. Nahed,et al.  Bone marrow response as a potential biomarker of outcomes in glioblastoma patients. , 2017, Journal of neurosurgery.

[20]  Jinming Yu,et al.  The prognostic significance of PD-L1 expression in patients with glioma: A meta-analysis , 2017, Scientific Reports.

[21]  Jasmin Herz,et al.  Myeloid Cells in the Central Nervous System. , 2017, Immunity.

[22]  G. Reifenberger,et al.  European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. , 2017, The Lancet. Oncology.

[23]  M. Lim,et al.  Immunotherapy and radiation in glioblastoma , 2017, Journal of Neuro-Oncology.

[24]  Andrew J. Park,et al.  Phase 2 study to evaluate safety and efficacy of MEDI4736 (durvalumab [DUR]) in glioblastoma (GBM) patients: An update. , 2017 .

[25]  J. Wargo,et al.  Hallmarks of response to immune checkpoint blockade , 2017, British Journal of Cancer.

[26]  Jedd D. Wolchok,et al.  T-cell invigoration to tumour burden ratio associated with anti-PD-1 response , 2017, Nature.

[27]  A. Brandes,et al.  OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143 , 2017 .

[28]  Zhihong Chen,et al.  Cellular and Molecular Identity of Tumor-Associated Macrophages in Glioblastoma. , 2017, Cancer research.

[29]  D. Hanahan,et al.  Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation , 2017, Science Translational Medicine.

[30]  D. Quail,et al.  The Microenvironmental Landscape of Brain Tumors. , 2017, Cancer cell.

[31]  P. Hamilton,et al.  Regulatory T cells promote myelin regeneration in the Central Nervous System , 2017, Nature Neuroscience.

[32]  W. Lim,et al.  The Principles of Engineering Immune Cells to Treat Cancer , 2017, Cell.

[33]  G. Mason,et al.  Severe cerebral edema following nivolumab treatment for pediatric glioblastoma: case report. , 2017, Journal of neurosurgery. Pediatrics.

[34]  Mariella G. Filbin,et al.  Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq , 2017, Science.

[35]  T. Korn,et al.  T cell responses in the central nervous system , 2017, Nature Reviews Immunology.

[36]  Alberto Mantovani,et al.  Tumour-associated macrophages as treatment targets in oncology , 2017, Nature Reviews Clinical Oncology.

[37]  Rakesh K. Jain,et al.  New Directions in Anti-Angiogenic Therapy for Glioblastoma , 2017, Neurotherapeutics.

[38]  Eilon D. Kirson,et al.  Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma , 2017 .

[39]  L. Recht,et al.  Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. , 2017, The Lancet. Oncology.

[40]  Xiuli Wang,et al.  Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. , 2016, The New England journal of medicine.

[41]  R. Fietkau,et al.  Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells , 2016, Front. Immunol..

[42]  Christopher M. Jackson,et al.  Anti–PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM , 2016, Science Translational Medicine.

[43]  M. Ciesielski,et al.  Novel vaccines for glioblastoma: clinical update and perspective. , 2016, Immunotherapy.

[44]  A. Faissner,et al.  The extracellular matrix niche microenvironment of neural and cancer stem cells in the brain. , 2016, The international journal of biochemistry & cell biology.

[45]  K. Tamura,et al.  ATIM-35. RESULTS OF THE PHASE IB KEYNOTE-028 MULTI-COHORT TRIAL OF PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH RECURRENT PD-L1-POSITIVE GLIOBLASTOMA MULTIFORME (GBM) , 2016 .

[46]  D. Merico,et al.  Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  R. Stupp,et al.  Tumor treating fields: a novel treatment modality and its use in brain tumors , 2016, Neuro-oncology.

[48]  M. Weller,et al.  Immunological effects of chemotherapy and radiotherapy against brain tumors , 2016, Expert review of anticancer therapy.

[49]  Voichita D. Marinescu,et al.  Heparanase Promotes Glioma Progression and Is Inversely Correlated with Patient Survival , 2016, Molecular Cancer Research.

[50]  Britta Engelhardt,et al.  Vascular, glial, and lymphatic immune gateways of the central nervous system , 2016, Acta Neuropathologica.

[51]  J. Kochenderfer,et al.  Toxicities of chimeric antigen receptor T cells: recognition and management. , 2016, Blood.

[52]  H. Colman,et al.  Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future , 2016, Current Treatment Options in Oncology.

[53]  M. Vetizou,et al.  Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. , 2016, Immunity.

[54]  Renier J. Brentjens,et al.  Driving CAR T-cells forward , 2016, Nature Reviews Clinical Oncology.

[55]  R. Weissleder,et al.  Extracellular Vesicles from High-Grade Glioma Exchange Diverse Pro-oncogenic Signals That Maintain Intratumoral Heterogeneity. , 2016, Cancer research.

[56]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[57]  R. Bourgon,et al.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.

[58]  V. Chekhonin,et al.  Temozolomide promotes genomic and phenotypic changes in glioblastoma cells , 2016, Cancer Cell International.

[59]  E. Hattingen,et al.  ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma. , 2016, Journal of the National Cancer Institute.

[60]  J. Kuo,et al.  CSF1 Overexpression Promotes High-Grade Glioma Formation without Impacting the Polarization Status of Glioma-Associated Microglia and Macrophages. , 2016, Cancer research.

[61]  W. Wels,et al.  Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival , 2016, Oncoimmunology.

[62]  Chih-Hao Chang,et al.  Emerging concepts of T cell metabolism as a target of immunotherapy , 2016, Nature Immunology.

[63]  J. P. McCoy,et al.  Effects of Systemically Administered Hydrocortisone on the Human Immunome , 2016, Scientific Reports.

[64]  S. Razavi,et al.  Immune Evasion Strategies of Glioblastoma , 2016, Front. Surg..

[65]  [World Health Organization classification of tumours of the central nervous system: a summary]. , 2016, Zhonghua bing li xue za zhi = Chinese journal of pathology.

[66]  F. Heppner,et al.  Resident microglia rather than peripheral macrophages promote vascularization in brain tumors and are source of alternative pro-angiogenic factors , 2016, Acta Neuropathologica.

[67]  S. Gabriel,et al.  Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.

[68]  H. Kaufman,et al.  Oncolytic viruses: a new class of immunotherapy drugs , 2015, Nature Reviews Drug Discovery.

[69]  D. Hafler,et al.  Prospects of immune checkpoint modulators in the treatment of glioblastoma , 2015, Nature Reviews Neurology.

[70]  M. Weller,et al.  Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. , 2015, Neuro-oncology.

[71]  M. Caligiuri,et al.  CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells , 2015, Scientific Reports.

[72]  M. Lim,et al.  Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites , 2015, Frontiers in Oncology.

[73]  Kevin J. Harrington,et al.  The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence , 2015, Nature Reviews Cancer.

[74]  S. Gautam,et al.  Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma , 2015, British Journal of Cancer.

[75]  Timothy J Keyes,et al.  Structural and functional features of central nervous system lymphatics , 2015, Nature.

[76]  C. Paulos,et al.  Harnessing the Microbiome to Enhance Cancer Immunotherapy , 2015, Journal of immunology research.

[77]  Elizabeth A. Repasky,et al.  Fever and the thermal regulation of immunity: the immune system feels the heat , 2015, Nature Reviews Immunology.

[78]  Maiken Nedergaard,et al.  The Glymphatic System: A Beginner’s Guide , 2015, Neurochemical Research.

[79]  Gelareh Zadeh,et al.  Glioblastoma: pathology, molecular mechanisms and markers , 2015, Acta Neuropathologica.

[80]  A. Sloan,et al.  Extra-CNS metastasis from glioblastoma: a rare clinical entity , 2015, Expert Review of Anticancer Therapy.

[81]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[82]  M. Lesniak,et al.  Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy , 2015, Oncoimmunology.

[83]  C. Sheridan.  IDO inhibitors move center stage in immuno-oncology , 2015, Nature Biotechnology.

[84]  S. Millis,et al.  HER2 expression status in diverse cancers: review of results from 37,992 patients , 2015, Cancer and Metastasis Reviews.

[85]  C. Dardis,et al.  Immunotherapeutic Advancements for Glioblastoma , 2015, Front. Oncol..

[86]  William A. Flavahan,et al.  Periostin Secreted by Glioblastoma Stem Cells Recruits M2 Tumor-associated Macrophages and Promotes Malignant Growth , 2014, Nature Cell Biology.

[87]  S. H. van der Burg,et al.  Therapeutic cancer vaccines. , 2010, The Journal of clinical investigation.

[88]  R. Daneman,et al.  The blood-brain barrier. , 2015, Cold Spring Harbor perspectives in biology.

[89]  David Fortin,et al.  Transforming growth factor-beta and its implication in the malignancy of gliomas , 2015, Targeted Oncology.

[90]  R. Jain,et al.  Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. , 2014, Cancer cell.

[91]  P. Wen,et al.  Immunotherapy advances for glioblastoma. , 2014, Neuro-oncology.

[92]  S. Sengupta,et al.  Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy. , 2014, Neuro-oncology.

[93]  I. Stratford,et al.  Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. , 2014, Cancer research.

[94]  T. Maruyama,et al.  Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma. , 2014, Journal of neurosurgery.

[95]  J. Joyce,et al.  Therapeutic targeting of tumor-associated macrophages and microglia in glioblastoma. , 2014, Immunotherapy.

[96]  Jeffrey W Pollard,et al.  Tumor-associated macrophages: from mechanisms to therapy. , 2014, Immunity.

[97]  R. Kurzrock,et al.  HER2 aberrations in cancer: implications for therapy. , 2014, Cancer treatment reviews.

[98]  Shawn M. Gillespie,et al.  Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma , 2014, Science.

[99]  Alexandre Corthay,et al.  Does the Immune System Naturally Protect Against Cancer? , 2014, Front. Immunol..

[100]  Katherine K. Matthews,et al.  Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. , 2014, Cancer research.

[101]  A. D. Van den Abbeele,et al.  Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma , 2014, Cancer Immunology Research.

[102]  Eduard Batlle,et al.  Metastatic stem cells: sources, niches, and vital pathways. , 2014, Cell stem cell.

[103]  T. Schwerdtle,et al.  Brain capillary pericytes contribute to the immune defense in response to cytokines or LPS in vitro , 2014, Brain Research.

[104]  Seth Love,et al.  Convection‐Enhanced Drug Delivery to the Brain: Therapeutic Potential and Neuropathological Considerations , 2014, Brain pathology.

[105]  K. Hoang-Xuan,et al.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[106]  K. Aldape,et al.  A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[107]  Susan M. Chang,et al.  Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. , 2014, Neuro-oncology.

[108]  P. Coulie,et al.  Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy , 2014, Nature Reviews Cancer.

[109]  M. Takeya,et al.  Clinical significance of macrophage heterogeneity in human malignant tumors , 2013, Cancer science.

[110]  B. Wei,et al.  The upregulation of programmed death 1 on peripheral blood T cells of glioma is correlated with disease progression , 2014, Tumor Biology.

[111]  Christina S. Leslie,et al.  CSF-1R inhibition alters macrophage polarization and blocks glioma progression , 2013, Nature Medicine.

[112]  F. Dammacco,et al.  MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. , 2013, Journal of the National Cancer Institute.

[113]  S. Ramakrishna,et al.  Immune system: a double-edged sword in cancer , 2013, Inflammation Research.

[114]  D. Bigner,et al.  Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. , 2013, Future oncology.

[115]  K. Aldape,et al.  Immune Heterogeneity of Glioblastoma Subtypes: Extrapolation from the Cancer Genome Atlas , 2013, Cancer Immunology Research.

[116]  R. Weller,et al.  Drainage of Cells and Soluble Antigen from the CNS to Regional Lymph Nodes , 2013, Journal of Neuroimmune Pharmacology.

[117]  C. James,et al.  Proteoglycans and their roles in brain cancer , 2013, The FEBS journal.

[118]  Y. Delneste,et al.  Efficiently stimulated adult microglia cross‐prime naive CD8+ T cells injected in the brain , 2013, European journal of immunology.

[119]  R. Kaur,et al.  Gliomas Promote Immunosuppression through Induction of B7-H1 Expression in Tumor-Associated Macrophages , 2013, Clinical Cancer Research.

[120]  P. Grandi,et al.  Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[121]  S. Demaria,et al.  Combining radiotherapy and cancer immunotherapy: a paradigm shift. , 2013, Journal of the National Cancer Institute.

[122]  C. Schroll,et al.  Bystander effects in tumor-free and tumor-bearing rat brains following irradiation by synchrotron X-rays , 2013, International journal of radiation biology.

[123]  スティーブン ジェイ． ブレイクモア，,et al.  How to treat cancer , 2013 .

[124]  A. Sica,et al.  Macrophage plasticity and polarization in tissue repair and remodelling , 2013, The Journal of pathology.

[125]  W. McBride,et al.  Regulatory T Cells in Radiotherapeutic Responses , 2012, Front. Oncol..

[126]  C. Chiang,et al.  Irradiation Promotes an M2 Macrophage Phenotype in Tumor Hypoxia , 2012, Front. Oncol..

[127]  Peng Zhang,et al.  Tumor-Associated Microglia/Macrophages Enhance the Invasion of Glioma Stem-like Cells via TGF-β1 Signaling Pathway , 2012, The Journal of Immunology.

[128]  Min Li,et al.  Understanding the role of cytokines in Glioblastoma Multiforme pathogenesis. , 2012, Cancer letters.

[129]  A. N. van den Pol,et al.  Oncolytic Virus Therapy for Glioblastoma Multiforme: Concepts and Candidates , 2012, Cancer journal.

[130]  M. von Knebel Doeberitz,et al.  Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol , 2012, BMC Cancer.

[131]  Christopher M. Jackson,et al.  Challenges in Immunotherapy Presented by the Glioblastoma Multiforme Microenvironment , 2011, Clinical & developmental immunology.

[132]  K. Margolin,et al.  Cytokines in Cancer Immunotherapy , 2011, Cancers.

[133]  S. Piantadosi,et al.  Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide , 2011, Clinical Cancer Research.

[134]  G. Merlino,et al.  The Two Faces of Interferon-γ in Cancer , 2011, Clinical Cancer Research.

[135]  C. von Kalle,et al.  MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[136]  H. Wishart,et al.  Immune Response in Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Intranodal Autologous Tumor Lysate-dendritic Cell Vaccination After Radiation Chemotherapy , 2011, Journal of immunotherapy.

[137]  J. Gui,et al.  Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. , 2011, Neuro-oncology.

[138]  K. Kurisu,et al.  Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[139]  A. Heimberger,et al.  Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? , 2011, Neuro-oncology.

[140]  R. Juliano,et al.  Extracellular Matrix of Glioblastoma Inhibits Polarization and Transmigration of T Cells: The Role of Tenascin-C in Immune Suppression , 2010, The Journal of Immunology.

[141]  Markus G. Manz,et al.  Development of Monocytes, Macrophages, and Dendritic Cells , 2010, Science.

[142]  F. Marincola,et al.  Immunobiological Characterization of Cancer Stem Cells Isolated from Glioblastoma Patients , 2010, Clinical Cancer Research.

[143]  C. Kim,et al.  Immunological Factors Relating to the Antitumor Effect of Temozolomide Chemoimmunotherapy in a Murine Glioma Model , 2009, Clinical and Vaccine Immunology.

[144]  Pieter Wesseling,et al.  Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. , 2009, Neuro-oncology.

[145]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[146]  J. Kuratsu,et al.  Possible involvement of the M2 anti‐inflammatory macrophage phenotype in growth of human gliomas , 2008, The Journal of pathology.

[147]  Gabriele Bergers,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[148]  R. McLendon,et al.  Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. , 2008, Neuro-oncology.

[149]  Erwin G. Van Meir,et al.  Erratum: Targeted cancer gene therapy using a hypoxia inducible factor-dependent oncolytic adenovirus armed with interleukin-4 (Cancer Research (2007) 67, (6872-6881)) , 2007 .

[150]  Erwin G. Van Meir,et al.  Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4. , 2007, Cancer research.

[151]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[152]  C. Chiang,et al.  Macrophages from irradiated tumors express higher levels of iNOS, arginase-I and COX-2, and promote tumor growth. , 2007, International journal of radiation oncology, biology, physics.

[153]  S. Demaria,et al.  Sensors of ionizing radiation effects on the immunological microenvironment of cancer , 2007, International journal of radiation biology.

[154]  Mary Helen Barcellos-Hoff,et al.  Isoform-Specific Activation of Latent Transforming Growth Factor β (LTGF-β) by Reactive Oxygen Species , 2006, Radiation research.

[155]  David J. Yang,et al.  The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. , 2006, Neuro-oncology.

[156]  K. Camphausen,et al.  Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy , 2006, The Journal of experimental medicine.

[157]  F. Pijpers,et al.  Therapeutic cancer vaccines , 2005, Nature Reviews Drug Discovery.

[158]  V. Kindler,et al.  B7-homolog 1 expression by human glioma: a new mechanism of immune evasion , 2005, Neuroreport.

[159]  F. Helmchen,et al.  Resting Microglial Cells Are Highly Dynamic Surveillants of Brain Parenchyma in Vivo , 2005, Science.

[160]  J. Schlom,et al.  Sublethal Irradiation of Human Tumor Cells Modulates Phenotype Resulting in Enhanced Killing by Cytotoxic T Lymphocytes , 2004, Cancer Research.

[161]  K. Iwamoto,et al.  A Sense of Danger from Radiation1 , 2004, Radiation research.

[162]  C. N. Coleman,et al.  Irradiation of Tumor Cells Up-Regulates Fas and Enhances CTL Lytic Activity and CTL Adoptive Immunotherapy , 2003, The Journal of Immunology.

[163]  Helga E de Vries,et al.  The Blood‐Brain Barrier and Its Role in Immune Privilege in the Central Nervous System , 2003, Journal of neuropathology and experimental neurology.

[164]  G. Finocchiaro,et al.  Dexamethasone inhibits the anti-tumor effect of interleukin 4 on rat experimental gliomas , 2003, Gene Therapy.

[165]  D. Carbone,et al.  VEGF as a mediator of tumor-associated immunodeficiency , 2001, Immunologic research.

[166]  I. Pastan,et al.  Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[167]  B. Quesnel,et al.  γ‐Ray irradiation induces B7.1 expression in myeloid leukaemic cells , 2000, British journal of haematology.

[168]  D. Carbone,et al.  Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. , 1998, Journal of immunology.

[169]  D. Bigner,et al.  The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. , 1998, Journal of neurovirology.

[170]  D M Coen,et al.  Experimental therapy of human glioma by means of a genetically engineered virus mutant , 1991, Science.